Overview

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Status:
Recruiting
Trial end date:
2022-09-15
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of SHR-1210 plus Apatinib versus AMD plus IFO in participants with soft tissue sarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Apatinib